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Background: Phenylketonuria (PKU) is an autosomal recessive disorder caused by the deficiency of phenylalanine
hydroxylase that catalyzes the conversion of phenylalanine to tyrosine, using tetrahydrobiopterin (BH4) as
coenzyme. Besides dietary phenylalanine restriction, new therapeutic options are emerging, such as the treatment
with BH4 in subgroups of PKU patients responding to a loading test with BH4.
Methods: A no-profit open-label interventional trial with long-term oral BH4 therapy, sponsored by the Italian
Medicines Agency (AIFA), was performed in a group of 17 PKU patients resulted as BH4 responders among 46
subjects analyzed for BH4-responsiveness (prot. FARM5MATC7). We report on efficacy and safety data of BH4
therapy and analyze factors predicting BH4-responsiveness and long-term response to BH4. A BH4-withdrawal
test was used as a proof of the efficacy of long-term therapy with BH4.
Results: Forty-four percent of the patients responded to the 48 h-long loading test with BH4. All the phenotypic
classes were represented. Genotype was the best predictor of responsiveness, along with lower phenylalanine levels
at diagnosis, higher tolerance and lower phenylalanine/tyrosine ratio before the test. In BH4 responder patients,
long-term BH4 therapy resulted safe and effective in increasing tolerance while maintaining a good metabolic
control. The BH4 withdrawal test, performed in a subset of patients, showed that improved tolerance was directly
dependent on BH4 assumption. Tolerance to phenylalanine was re-evaluated in 43.5% of patients and was
longitudinally analyzed in 5 patients.
Conclusions: Long-term treatment with BH4 is safe and effective in increasing tolerance to phenylalanine. There is
real need to assess the actual tolerance to phenylalanine in PKU patients to ameliorate quality of life, improve
nutritional status, avoiding unnecessarily restricted diets, and interpret the effects of new therapies for PKU.
Keywords: Phenylalanine hydroxylase deficiency, Phenylketonuria, Tetrahydrobiopterin, Sapropterin,
Hyperphenylalaninemia, Therapy, Tolerance, Safety, Side effectsBackground
Phenylketonuria (PKU; MIM 261600) is an autosomal re-
cessive disorder caused by the deficiency of phenylalanine
hydroxylase (PAH, EC 1.14.16.1), a liver enzyme that
catalyzes the conversion of phenylalanine (Phe) to tyrosine
(Tyr), using tetrahydrobiopterin (BH4) as coenzyme. To* Correspondence: andria@unina.it
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unless otherwise stated.date, more than 500 causative mutations of the PAH gene
have been identified (http://www.pahdb.mcgill.ca; http://
www.biopku.org). In spite of the continuum spectrum of
phenotypes, PKU is classified into classic PKU (cPKU),
moderate PKU (moPKU) and mild PKU (mPKU) accord-
ing to plasma Phe levels at diagnosis and tolerance, de-
fined as the highest Phe intake able to keep blood Phe
levels within the safe range [1]. In addition, hyperphenylal-
aninemia is divided in mild hyperphenylalaninemia
(HPA)-gray zone, requiring dietary protein restriction,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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below 360 micromol/L and no treatment is required [1].
Untreated PKU leads to neurological abnormalities,
while early treatment with a Phe-restricted diet prevents
brain damage and results in almost normal neurological
development [2]. Unfortunately, this dietary regimen is
often complicated by psychological discomfort and re-
duced compliance to the diet after the first years of life.
Initial reports supported the possibility to loosen diet
during adulthood; however, as defects of executive func-
tions and brain hypomyelination may occur in patients
with poor metabolic control [3,4], a life-long restricted
dietary therapy has been recommended. Since 1999,
several independent reports have shown that BH4 can
decrease plasma Phe levels and increase Phe oxidation
to Tyr [5-19] by acting as a chemical chaperone [20,21]
in patients defined as BH4 responders. Responsiveness
to BH4 has been arbitrarily defined as a reduction of at
least 30% of plasma Phe levels during a loading test with
BH4 compared to the baseline Phe value [22]. The
prevalence of BH4 responsiveness is variable in different
studies, ranging from 20% [9] to 62% [23]. Besides the
interplay among the PAH enzyme, the coenzyme (BH4)
and the substrate (Phe), the difference in the rate of
BH4-responder patients also resides in the protocols
varying in duration (24 h, 48 h, 1 week or 4 weeks) and
in BH4 testing dose (10 mg/kg vs 20 mg/kg of body
weight) [24]. Reports on long-term treatment with BH4
show that BH4 allows a better metabolic control and a
diet relaxation without serious adverse effects. Two ran-
domized placebo-controlled trials reported a significant
lowering of blood Phe concentration in the BH4 group
after 6 weeks [11] and improvement of Phe tolerance
after 10 weeks [13]. The improvement of Phe intake
with BH4 was also observed in subsequent studies
[13,15-19,25]. Recent reports attempted to establish
predictors of BH4 responsiveness and of BH4 long-term
response, including Phe levels at diagnosis, Phe/Tyr ra-
tio, Phe tolerance before BH4 treatment and genotype
[19]. US recommendations for the use of BH4 in PKU
have been recently published, but some questions are
still open such as i) variability of response to BH4 and
therapeutic effects in subpopulations, ii) long-term effi-
cacy and safety outcomes, iii) effects of diet liberalization
on nutritional status and iv) risk of dietary overtreatment,
especially in critical periods such as infancy, adolescence
or pregnancy [1].
In this study, we show the results of a no-profit open-
label interventional trial with long-term oral BH4 ther-
apy. The trial started in 2006 and ended in September
2009, date of marketing of sapropterin dihydrochloride
(Kuvan®, Merck-Serono), the synthetic form of BH4. A
long-term follow-up continued from September 2009
to December 2013. We report on efficacy and safetydata of BH4 therapy and analyze factors predicting
BH4-responsiveness and long-term response to BH4.
We finally report on a BH4-withdrawal test, used as a
proof of the efficacy of long-term therapy with BH4,
and on the reassessment of Phe tolerance in a subgroup of
patients who underwent the BH4 responsiveness protocol.
Methods
Patients
Forty-six patients with HPA due to PAH deficiency were
recruited at the Federico II University, Naples, and the
Magna Graecia University, Catanzaro, Italy after ethical
committee approval (Prot. n. 239/06) and written informed
consent.
Inclusion criteria were: age >4 years, PKU/hyperphe-
nylalaninemia requiring dietary restriction, complete
genotyping of PAH gene, compliance to study proce-
dures, provision of a written informed consent. Patients
with concurrent diseases that would interfere with en-
rolment or safety, with concomitant drug treatment,
with clinical diagnosis of primary BH4 deficiency or un-
available for study participation were excluded from the
study. Patients fulfilling the inclusion criteria entered
into the study protocol supported by the Italian Medi-
cines Agency (AIFA) (prot. FARM5MATC7; EudraCT
code: 2006-005768-22). Patients were phenotypically
classified according to Phe blood value before dietary
treatment and to Phe tolerance, determined at 5 years of
age (historical tolerance). Four different phenotypes were
identified: 1) classic PKU (cPKU; Phe >1200 micromol/L;
tolerance <350 mg/day), 2) moderate PKU (moPKU; Phe
900-1200 micromol/L; tolerance 350-400 mg/day), 3) mild
PKU (mPKU; Phe 600-900 micromol/L; tolerance 400-
600 mg/day), and 4) mild HPA-gray zone (henceforth
called mHPA; 360-600 micromol/L; tolerance >600 mg/day),
requiring dietary protein restriction [1]. When a discrepancy
was noted between pre-treatment blood Phe levels and Phe
tolerance, patients were classified according to Phe tolerance.
Thirty-nine percent of patients were cPKU, 14% were
moPKU, 35% were mPKU and 12% were mHPA requiring
low protein diet. Age at loading test, gender, phenotypic
class, molecular analysis and predicted residual activity (PRA)
of each mutation in responders and non-responders, as
reported in the BIOPKU database (http://www.biopku.org),
are shown in Additional file 1. All patients were genotyped
by direct sequencing of the PAH gene [26]. Plasma Phe
and Tyr were analyzed by amino acid analyzer (Beckman
System 6300).
Assessment of BH4 responsiveness
Pre-loading test protocol
Each patient was asked to comply to the assigned diet
with Phe amounts corresponding to the known Phe toler-
ance and equally distributed in three main meals. Patients
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The dietary regimen had to be followed for at least two
weeks before the BH4 loading test. In the week before the
BH4 loading test, blood Phe and Tyr were analyzed twice
a week after an overnight fast to verify the compliance to
diet on the basis of Phe values. Only a 15% variance
between the two Phe values was accepted. If plasma Phe
resulted ≥ 400 micromol/L, the BH4 loading test was
started; if plasma Phe resulted < 400 micromol/L, dietary
Phe intake was increased every 10-15 days until blood Phe
resulted ≥ 400 micromol/L.
BH4 loading test
A 48 h-long BH4 loading test was performed with BH4
tablets (Schircks Laboratories, Switzerland) in two oral
doses of 20 mg/kg at T0 and T24 hours. Plasma Phe and
Tyr were analyzed at 0, 4, 8, 12, 24, 32 and 48 hours. Pa-
tients were hospitalized during the loading test to ensure
optimal compliance. BH4-responsiveness was defined by
a reduction of Phe levels >30% from the baseline Phe
value. Patients were defined as rapid responders if >30%
reduction of blood Phe levels occurred within the first
24 h of the test, and as slow-responders if the response
was observed between T24 and T48.
Long-term therapy with BH4
BH4-responder patients started a long-term treatment
with BH4 at the initial dose of 10 mg/kg/day. In some
patients, the dose was changed based on the metabolic
control. During the trial, all patients assumed 50 mg
BH4 tablets (Schircks Laboratories), divided in three oral
doses before meals, until September 2009, when therapy
was shifted to sapropterin. Phe intake was increased
by standard food exchange lists ranging from 75 to
225 mg/day, every 15-30 days if Phe levels resulted
within the target. Plasma Phe was always dosed after
the overnight fast. The reference Phe values in differ-
ent age groups were those reported for our country
in Blau et al. [27] and in the recommendations of the
Italian Society for the Study of Inborn Errors of
Metabolism and Neonatal Screening [28], i.e. 120-360
micromol/L until 12 years of age and 120-600 micro-
mol/L for older ages.
Outcome measures were improvement of metabolic
control and of tolerance to Phe. Median plasma Phe ob-
tained during the 5 years preceding BH4 treatment was
used as index of metabolic control before BH4 and com-
pared with plasma Phe levels obtained during BH4 ther-
apy. Dietary Phe intake (mg/day) was assessed before
starting and during BH4 therapy. A three days meal
diary was analyzed at each visit. Response to long-term
therapy with BH4 was defined by a significant increase
of Phe intake compared to the historical tolerance and
to tolerance before BH4.BH4 withdrawal test
Seven patients (2 moPKU, 3 mPKU and 2 mHPA) aged
16 to 20 years on long-term treatment (28-35 months)
with sapropterin undertook a BH4 withdrawal test as a
confirmatory proof of efficacy of BH4 therapy, after par-
ents/patients’ agreement. Patients were asked to check
plasma Phe levels twice during the 10 days before the
test (day -10 and -5; BH4-1). BH4 therapy was then
withdrawn for additional 10 days and Phe levels were
assessed at day +5 and +10 from the discontinuation of
the drug (Withdrawal). Patients were finally asked to re-
start BH4 and to control plasma Phe levels 10 days later
(day +20) (BH4-2).
Safety and tolerability
Anamnestic records were used to investigate the occur-
rence of adverse events. Complete physical examination
was performed monthly by the primary care physician
and every three months by the physicians in each
recruiting centre. Nutritional status (hemoglobin, iron,
total proteins, albumin, plasma amino acids profile, vita-
min B12, folic acid), liver and kidney functions were also
analyzed.
Statistical analysis
Normality of continuous data was assessed by the
Levene’s test. The Student’s t-test was used to compare
means and the Mann-Whitney U-test to compare me-
dians. Related continuous data were analysed by the
Wilcoxon test. Pearson's correlation coefficient (r) was
used to measure the strength of the association between
two variables. The Chi-square test was used for categor-
ical data. Variance was calculated as a measure of Phe
variability before and during BH4. A two-tailed p-value
<0.05 was assumed as statistical significant. Statistical
analysis was performed by SPSS 17.0 software.
Results
Reassessment of tolerance to phenylalanine
To achieve stable Phe values at the minimal concentra-
tion of 400 micromol/L, a pre-test protocol was devel-
oped. During this period, in a subgroup of patients, we
noted that, despite the gradual increase of dietary Phe,
plasma Phe did not increase as expected and diet adjust-
ments had to be repeated for 2-3 times until the 400
micromol/L threshold was reached. These observations
were made in 20 out of 46 enrolled patients (43.5%).
Tables 1 and 2 report genotype, historical tolerance, the
median plasma Phe level before enrolment and the new
Phe intake. In the first set of 10 patients (Table 1),
plasma Phe persistently remained <360 micromol/L
despite dietary Phe increased from 1.3-to 3.2 folds com-
pared to the baseline tolerance. A final substantial in-
crease of dietary Phe had to be done to exceed the 400
Table 1 Patients with Phe < 360 micromol/L during the pre-loading test protocol
Subject (#) PAH genotype Historical
tolerance*
Median plasma Phe New Phe intake
(10 th -90 th centile)§ [Phe values]
3 R261Q/R158Q 400 360 (180-570) 786 [390; 376]
7 L48S/R158Q 505 246 (120-318) 1321 [264; 282]
10 R261Q/R261Q 410 204 (130-372) 817 [330; 380]
12 R261Q/P281L 410 100 (60-180) 1328 [198; 228]
13 L48S/R158Q 410 840 (300-1080) 1133 [290; 324]
14 L48S/R158Q 440 426 (200-540) 978 [300; 348]
18 L48S/R158Q 650 246 (120-360) 1342 [210; 234]
22 R261Q/IVS10nt-11G > A 345 372 (100-700) 950 [330; 360]
23 R261Q/IVS10nt-11G > A 340 336 (102-588) 660 [336; 348]
42 IVS06nt-2delA/P281L 630 336 (110-480) 850 [290; 340]
Notes. *Historical tolerance (mg Phe/day) calculated at 5 years of age; §Median plasma Phe (micromol/L) calculated from Phe values of the 5 years preceding the
inclusion into the study; the new Phe intake (mg Phe/day) represents the dietary Phe assigned during the pre-loading test protocol with the corresponding
plasma Phe values (two determinations), reported in square brackets. In all these patients, an additional final increase of dietary Phe was made to reach Phe
values ≥ 400 micromol/L as required for the BH4 loading test.
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second group of 10 patients (Table 2), up to three diet
adjustments were sufficient to reach plasma Phe values
>400 micromol/L. In this group, we noted that the max-
imum plasma Phe concentration was 600 micromol/L,
within the upper reference range for age group, and that
in some subjects Phe values were not different from the
median plasma Phe of the five years before the inclusion
in the study. However, dietary Phe increased from
1.6- to 6.3-folds from the baseline. Neither the pheno-
typic class nor the genotype appeared to be predictive
of the increase of Phe intake.
BH4 loading test
Subjects
Forty-three patients out of 46 correctly completed the
BH4 loading test (Additional file 2). Nineteen out of 43Table 2 Patients with Phe >400 micromol/L during the pre-lo











40 IVS10nt-11G > A/F39del(116118delTCT) 39
Notes. *Historical tolerance (mg Phe/day) calculated at 5 years of age; §Median plas
inclusion into the study; the new Phe intake (mg Phe/day) represents the dietary Ph
plasma Phe values (two determinations), reported in square brackets.patients (44%) resulted as BH4-responders: 2 (10.5%)
were cPKU, 4 (21%) were moPKU, 10 (52.5%) were
mPKU and 3 (16%) were mHPA. Among non-responders,
19 (79%) were cPKU, 2 (8.5%) were moPKU, 1 (4%) was
mPKU and 2 (8.5%) were mHPA. According to the pheno-
typic class, response to BH4 was detected in 9.5% of 21
cPKU, 66.6% of 6 moPKU, 91% of 11 mPKU and 60% of 5
mHPA.
Genotypes
The most common PAH allelic variants found among
BH4-responders were p.R261Q (23.7%), p.L48S (23.7%),
p.R158Q (18.4%) and p.P281L (10.5%). The latter muta-
tion, with low predicted enzymatic activity, was associ-
ated with the p.R261Q mutation in all cases. In the
BH4-responder group, all mutations were missense ex-
cept two (165delT and IVS10nt-11G > A). Two patientsading test protocol
istorical
lerance*
Median plasma Phe New Phe intake
(10 th -90 th centile)§ [Phe values]
0 780 (370-900) 1335 [432; 456]
5 168 (30-582) 1228 [510; 546]
5 150 (100-174) 711 [492; 552]
0 174 (140-222) 1995 [438; 444]
0 510 (330-570) 3187 [590; 526]
00 534 (360-540) 2658 [516; 486]
20 540 (420-600) 3187 [516; 600]
0 456 (180-864) 963 [468; 486]
0 600 (318-720) 1164 [600; 582]
0 366 (100-444) 670 [360; 408]
ma Phe (micromol/L) calculated from Phe values of the 5 years preceding the
e assigned during the pre-loading test protocol with the corresponding
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activity is still unknown. However, as in both cases this
mutation was associated with the c.165delT variant,
known to be non-responsive to BH4 [29], the p.P366H
mutation can be associated with BH4-responsiveness.
Among BH4 non-responders, the IVS10nt-11G > A allele
accounted for 19% of total alleles, followed by the
p.R261Q (10.6%), the p.P281L (10.6%) and the p.R158Q
(8.5%) mutations. Overall, splice mutations accounted
for 42% of the total alleles found in non-responder
patients.
Rate of response
As shown in Table 3 and Figure 1, the reduction of
blood Phe from the baseline among BH4 responders
ranged between 33.3% and 77.1%. The rate of Phe
reduction during the test was largely independent from
the phenotypic class. Nine patients (47%) showed a
rapid response and 10 patients (53%) a slow response.
Both cPKU patients and 3 out of 4 moPKU showed a
slow response; considering together mPKU and mHPA
subjects, 61% showed a rapid response and 39% a slow
response. Data analysis showed a tendency toward
significance of the association between pre-treatment
Phe at diagnosis and the rapidity of response, being
lower Phe levels better predictors of a response to BH4Table 3 Response to BH4-loading test according to the pheno




1 cPKU R261Q/P281L 13 40
2 cPKU R261Q/P281L 11 41
3 moPKU R261Q/R158Q 17 33.3
4 moPKU R261Q/L48S 14 66.6
5 moPKU R261Q/P281L 14 36.8
6 moPKU L48S/Q301P 7 77.1
7 mPKU L48S/R158Q 14 48
8 mPKU L48S/D222G 12 58
9 mPKU 165delT/P366H 18 67
10 mPKU R261Q/R261Q 13 44
11 mPKU R261Q/IVS10nt-11G > A 20 34
12 mPKU R261Q/P281L 17 47.3
13 mPKU L48S/R158Q 21 60
14 mPKU L48S/R158Q 10 53
15 mPKU L48S/L48S 5 80
16 mPKU R158Q/Y414C 12 52
17 mHPA R158Q/D338Y 14 54.6
18 mHPA L48S/R158Q 19 45
19 mHPA 165delT/P366H 22 59within the first 24 h of the test [Phe at diagnosis (mean
± SD) in rapid responders 853 ± 450 micromol/L; Phe at
diagnosis (mean ± SD) in slow responders 1305 ± 500
micromol/L; p = 0.057].
The percentage of Phe reduction during the loading
test was greater among rapid responders compared to
slow-responders [mean % of reduction ± SD in rapid
responders: 60 ± 10; mean % of reduction ± SD in slow
responders: 45.5 ± 12; p = 0.009] and was inversely
correlated with Phe values during the 5 years prior to
the BH4 loading test (r = -0.6; p = 0.008). The percent-
age of Phe reduction during the test correlated nei-
ther with Phe at diagnosis nor with tolerance (p >
0.05) but was associated with the genotype and was
greater when two alleles with PRA > 1% were present
(p < 0.05). Taken together these observations indicate that
all phenotypic classes are eligible for the assessment of
response to BH4 and that all patients should be advised to
perform a 48 h-long loading test, even if the majority of
milder HPA phenotypes will respond within the first 24 h
of the test.Predictors of BH4 responsiveness
Lower Phe levels at diagnosis, higher Phe tolerance, the
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Slow 644 51 12.6
Slow 768 62 12.3
Rapid 434 44 9.8
Slow 689 66 10.4
Slow 556 44 12.6
Slow 538 59 9.1
Rapid 446 67 6.6
Rapid 605 42 14.4
Rapid 680 51 13.3
Slow 600 53 11.3
Slow 1024 45 22.7
Rapid 726 53 13.6
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Slow 522 54 9.6



















































Figure 1 Results of the 48 h-BH4 loading test (20 mg/kg/day) of the 19 HPA responder subjects according to their phenotypic class.
Cumulative data at each time-point are shown as mean ± SD, except for the 2 cPKU patients where only mean value is represented.
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response to BH4 (Table 4).
Long-term therapy with BH4
Two BH4-responder patients (#15, 16) did not agree to
the long-term treatment with BH4. Seventeen patients
(2 cPKU, 4 moPKU, 8 mPKU and 3 mHPA) started a
long-term treatment with BH4 (Schircks Laboratories).
Five patients were adults when BH4 therapy was started
(#9, 11, 13, 18, 19). From 2009, all patients shifted to
sapropterin (Kuvan®) and all started with one morning
dose, as indicated by the manufacturer. However, over a
short-term follow-up, 15/17 patients (88%) worsened
their metabolic control. The daily dose was again divided
in three and the Phe values returned to the previous
levels. The follow-up ranged from 60 to 84 months, with
the exception of patient #11 who resulted as pseudo-
responder and discontinued the therapy after 12 months.
At the end of the follow-up period, 12 patients were
adults (age range 18-29 years). Patients who resulted asTable 4 Predictors of BH4-responsiveness
BH4 responders (N
Gender 11 M/8 F
Age (years) at BH4 loading test (Mean ± SD) 14.4 ± 4.5
Phe§ at diagnosis (Mean ± SD) 1148 ± 613
Phe tolerance* [Mean (range)] 549 (235-1920)
Genotype One allele with PRA > 1% 17
Two alleles with PRA > 1% 13
Phe§ at loading test (T0) (Mean ± SD) 615 ± 180
Tyr§ at loading test (T0) (Mean ± SD) 52.35 ± 8.5
Phe/Tyr at loading test (T0) 12.58 ± 4.5
*Phe tolerance (mg/day), as calculated at 5 years of age. § Phe and Tyr plasma concBH4 responders and started the long-term treatment
during adolescence, maintained the same metabolic
control at the same dietary regimen during adulthood.
Tolerance increased in all cases by 2.3- to 11.6-folds
compared to the historical tolerance, as calculated at
5 years of age (Table 5). Mean tolerance was 583 ±
443 mg Phe/day before BH4 therapy and 2798 ±
1568 mg Phe/day during BH4 treatment (p < 0.0001).
Significant increases of Phe intake were also observed
when tolerance on BH4 therapy was compared to the
reassessed Phe intake before BH4, as reported in
Tables 1 and 2. Nine out of 17 patients (53%) reached a
Phe intake ≥ 3000 mg/day with no need of amino acids
and vitamin supplements. Two mPKU patients (#10, 12)
reached a daily Phe intake of 2392 and 2278 mg/day,
respectively and needed only small amounts of amino
acids and vitamin supplements.
In spite of the increase of dietary Phe, both groups of
patients treated either with sapropterin plus diet or
with sapropterin alone maintained an optimal metabolic= 19) BH4 non-responders (N = 24) p-value
9 M/15 F 0.18
13.6 ± 4.8 0.63




695 ± 228 0.2
48.12 ± 12.4 0.36
16.9 ± 5.1 0.01
entrations are expressed in micromol/L. PRA: predicted residual activity.
Table 5 Phe tolerance and plasma Phe of responder patients on long-term treatment with BH4
Subject (#) Phenotype Follow-up
(months)
Tolerance at







(10 th -90 th centile)
Median plasma
Phe on BH4
(10 th -90 th centile)
1 cPKU 80 280 280 1180 552 (120-588) 492 (276-600) NS
2 cPKU 60 325 325 1010 240 (180-300) 480 (246-522)*
Mean 302.5 302.5 1095
Median (10 th -90 th centile) 426 (210-780) 492 (300-600) NS
3 moPKU 84 400 786 1386 360 (180-570) 468 (384-600) NS
4 moPKU 80 360 1335 4185 780 (370-900) 140 (102-170)*
5 moPKU 79 395 1228 4000 366 (100-444) 312 (180-354)*
6 moPKU 66 385 711 1611 150 (100-174) 258 (90-282)**
Mean ± SD 385 ± 17* 1015 ± 312* 2795.5 ± 1502
Median (10 th -90 th centile) 310 (90-756) 495 (180-780)**
7 mPKU 80 505 1321 3800 246 (120-318) 540 (240-660)**
8 mPKU 75 450 1995 4700 174 (140-222) 228 (126-360)NS
9 mPKU 75 550 3187 5000 510 (330-570) 560 (372-600)NS
10 mPKU 60 410 817 2392 204 (130-378) 450 (348-600)**
11 mPKU 12 440 440 1188 162 (100-300) 600 (400-660)**
12 mPKU 60 410 1328 2278 100 (60-180) 456 (360-600)**
13 mPKU 61 410 1133 3000 840 (300-1080) 516 (264-600)NS
14 mPKU 61 440 978 1950 426 (200-540) 402 (216-540)NS
Mean ± SD 451 ± 50.7** 1400 ± 851* 3038 ± 1351
Median (10 th -90 th centile) 240 (90-660) 534 (200-780)**
17 mHPA 84 1500 2658 5000 534 (360-540) 250 (170-300)**
18 mHPA 80 650 1342 4000 246 (120-360) 480 (360-600)NS
19 mHPA 72 1920 3187 4500 540 (420-600) 360 (270-600)*
Mean ± SD 1356 ± 637** 2395 ± 950* 4500 ± 500
Median (10 th -90 th centile) 468 (204-570) 432 (210-600)NS
Overall (Mean ± SD) 583 ± 443** 1627 ± 988** 2798 ± 1568
Overall
Median (10 th -90 th centile)
320 (130-730) 490 (198-770)**
§Calculated from Phe concentrations (micromol/L) of the 5 years preceding the start of BH4 therapy; Wilcoxon Z-test was used for intrasubject
analysis; Mann-Whitney U-test was used to compare patients’ groups. *p < 0.05; **p < 0.01, NS: not significant. Tolerance (mg Phe/day) on BH4 was
compared to both tolerance calculated at 5 years of age and tolerance before BH4 therapy for patients # 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 17, 18, 19 (see Tables 1 and 2).
For patients # 1, 2 and 11, tolerance pre-BH4 was consistent with tolerance at 5 years of age. For the cPKU group (only two patients), no statistical analysis is given
for tolerance.
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blood Phe ≤360 micromol/L; the remaining subjects had
median Phe values <600 micromol/L, within the recom-
mended range for age group considered for the study
(Table 5). Intra-subject analysis showed that median
plasma Phe levels on BH4 significantly decreased in 4
patients, remained stable in 7 patients and increased in
6 patients compared to the median plasma Phe pre-BH4
(Table 5). When all patients data were combined, me-
dian plasma Phe levels on BH4 raised from 320 to 490
micromol/L, although remaining into the reference
range for age group (Table 5). Analysis of variance of
Phe levels before and during BH4 failed to show asignificant decrease of Phe variability on BH4 therapy
(p = 0.6).
The new tolerance under BH4 therapy significantly cor-
related with the historical tolerance (r = 0.52; p = 0.03).
The percentage of Phe reduction during the loading test
and the rapid vs slow response to BH4 did not correlate
with the new tolerance and the median Phe values under
BH4.
No difference was noted in nutritional status under
BH4 therapy. During the treatment, body mass index
(BMI) of all BH4 responders increased from 21,7 ± 2,1 to
23,6 ± 1,39 (p = 0.006). This difference was detected
among patients treated with BH4 + diet and was mainly
Scala et al. Orphanet Journal of Rare Diseases  (2015) 10:14 Page 8 of 12present in mPKU and moPKU patients (p = 0.008 and
p = 0.02, respectively; Additional file 3).
All patients were confirmed as true responders to BH4
after a long-term follow-up, with the exception of patient
#11. Notably, other 3 patients with the same genotype re-
sulted non-responder to BH4, thus suggesting that the
genotype p.R261Q/IVS10nt-11G >A is predictive of non-
responsiveness.
BH4 withdrawal test
A BH4 withdrawal test was performed to add an add-
itional proof of efficacy of sapropterin therapy. Before
therapy withdrawal, all patients were in good metabolic
control. During the test, all patients, under a constant
diet, showed an increase of plasma Phe ranging from 31
to 87%. After the reintroduction of sapropterin, plasma
Phe levels returned to pre-test values (Figure 2).
Safety and tolerability
Both tetrahydrobiopterin (Schircks Laboratories) and
sapropterin (Kuvan®, Merck-Serono) were generally safe
and well tolerated. During the long-term follow-up, ad-
verse events were recorded in 7 patients (41%). In three
patients, symptoms were likely associated with the treat-
ment. The first patient (#3), treated with sapropterin at
15 mg/kg/day, after 26 months of follow-up, complained
of epigastric pain and nausea over a period of two
months. A trial with ranitidine failed to reduce symp-
toms. Sapropterin dose was reduced to 10 mg/kg/day
with clinical improvement and then withdrawn with
complete resolution of symptoms. After 2 months of
wellbeing, sapropterin therapy was reintroduced withSu



















































Figure 2 BH4 withdrawal test in 7 patients. Median Phe before BH4 the
to the enrolment into the trial (Baseline). Values reported in BH4-1 and Wit
and -5, and at +5 and +10 days from BH4 withdrawal, respectively. Patients
10 days later (day +20) (BH4-2). Numbers reported in the bars represent th
the dietary Phe intake during the withdrawal test (dark columns). The dash
the age group (600 micromol/L).no clinical problems. Two patients (#6, 13) complained
of headache, a known side effect of sapropterin. Gastro-
intestinal symptoms also occurred in two male patients
(#5, 17). Patients were admitted to the hospital for acute
abdominal pain, increased neutrophil count and C-
reactive protein, and ultrasonographic signs of acute
appendicitis. Both patients temporary stopped BH4
therapy and recovered after antibiotic therapy with no
need of surgery. After one month, they restarted therapy
with no additional side effects. Adverse events, unlikely
linked to the therapy, were reported in additional three
patients. A first patient (#18), a 23-year-old boy treated
for 5 years, developed mild anorexia and food avoidance.
He never required hospitalization and his nutritional sta-
tus remained good all over the period. Dosage was ad-
justed to the new weight and the drug was continued. A
second male patient (#12) experienced psychotic symp-
toms after a four years follow-up. The symptoms recov-
ered after pharmacological treatment and sapropterin was
continued in order to keep Phe levels low. Finally, a third
male patient (#7) was diagnosed with testicular seminoma.
Pregnancy was detected in a 23-year-old girl in follow-
up for 24 months. Sapropterin was withdrawn at the 7th
week of gestational age. The patient kept a good meta-
bolic control with diet alone throughout the pregnancy.
The baby presented normal at birth and he is still in
good health after a 12 months follow-up.
Long term follow-up of BH4 non-responder patients
BH4 non-responder patients returned to the previous
dietary regimen with the exception of the 6 subjects (#
22, 23, 25, 39, 40, 42) reported in Tables 1 and 2, whobjects



































rapy was calculated on Phe values collected during the 5 years prior
hdrawal represent the mean values of the Phe concentration at -10
were finally asked to re-start BH4 and to control plasma Phe levels
e daily Phe intake (mg/day) before BH4 therapy (white column) and
ed line indicates the plasma Phe upper value of the target range for
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the new established Phe intake. Of these, one patient
(#39) was excluded because he decided to start large
neutral amino acids (LNAA) treatment. Data on the
remaining 5 subjects are reported in Additional file 4.
The increase of dietary Phe over a five years period
ranged from 1.3 to 3-folds compared to the historical
baseline. At the end of the follow-up, the Phe daily in-
take was in all cases >600 mg Phe/day. The metabolic
control improved in two subjects (# 22, 25), remained
stable in subjects #23 and 42 and worsened in subject
#40, although the median plasma Phe was <400 micro-
mol/L. Median blood Phe was <360 micromol/L in three
subjects and between 360 and 380 micromol/L in the
other two patients.
Discussion
Reassessment of Phe tolerance
Phe tolerance is not a clear-cut parameter, since it de-
pends on the Phe target concentration that varies among
countries and age-groups [27]. Blood Phe (and conse-
quently Phe tolerance) may be influenced by protein ca-
tabolism in the neonatal period [30], illnesses, rapid
growth during the first months of life and adolescence,
and changes in body composition in adulthood. In the
daily clinical practice, an unchanged Phe restricted diet
may be prescribed for years if blood Phe concentrations
remain within the target range, even though protein re-
quirement may have increased [31]. Variation of Phe tol-
erance with increasing age is still an unsolved question.
van Spronsen and colleagues in 2009 reported that Phe
tolerance at 2, 3 and 5 years correlates with tolerance at
10 years [32]. To the best of our knowledge, Phe toler-
ance beyond adolescence was reassessed in only 8 adult
PKU subjects [33]. Tolerance expressed as mg Phe/day
increased in all cases with the exception of one patient.
The authors speculated that dietary Phe intake was
probably not adequate to support protein turnover for
patients’ current body mass.
In our study, the BH4 loading test gave us the oppor-
tunity to question and re-evaluate our classification of
some patients based on Phe tolerance, as defined at
5 years of age. First of all, re-evaluation of Phe tolerance
was necessary only in a proportion of patients, namely
in 6/24 BH4 non-responder patients and in 14/19 re-
sponders. With the exception of a 7 year-old male, pa-
tients’ age ranged from 12 to 24 years (Additional file 1).
In the remaining patients, no variations of Phe tolerance
were noted. Table 1 shows patients that under the in-
creased dietary regimen maintained Phe values < 360
micromol/L, the same upper reference limit considered
at 5 years of age and until adolescence. Although we
recognize that two blood determinations are insufficient
to draw definite conclusions, we can speculate that inthis set of patients, phenotypic classification based on
tolerance at 5 years of age was wrong and that those pa-
tients were unnecessary overtreated. Table 2 shows pa-
tients that under the new Phe intake showed blood Phe
values between 360 and 600 micromol/L. Despite Phe
levels were above the upper reference limit used at
5 years of age (when tolerance was assessed), Phe values
remained within the target range for age-group.
Over a five years follow-up, 4 out of 5 patients improved
their metabolic control or remained stable probably be-
cause of better adherence to diet, less catabolic processes
or both. Finally, as recent data are drawing an intriguing
scenario of interactions between PAH mutated enzyme
and the substrate [34] a cooperative interaction between
mutated alleles and Phe may not be excluded.
BH4 loading test
Subjects
Responsiveness to BH4 was observed in all phenotypic
classes, including 9.5% of cPKU subjects. This observation
retraces previous reports of BH4 response also in cPKU
[18,23]. In addition, more than half of the enrolled pa-
tients with moPKU responded to BH4, showing that the
phenotype alone is not a good predictor of response to
BH4, but other factors must be taken into consideration.
Genotypes
The presence of at least one mutation with residual en-
zymatic activity resulted the best predictor of BH4-
responsiveness in our cohort of patients. Residual PAH
activity was strongly associated with response, while the
presence of two inactive alleles excluded responsiveness.
As expected, missense mutations were prevalent among
BH4 responder patients (95%), while splice mutations
were prevalent among non-responders. The p.R261Q
mutation combined with a missense mutation was al-
ways associated with responsiveness while, when asso-
ciated with a splice mutation, it was associated with
non-responsiveness, except for the case of patient #11,
who resulted a pseudo-responder (Additional file 1).
The p.L48S mutation was found in BH4 responder pa-
tients except for one non-responder patient, homozygous
for this PAH variant. The p.Y414C mutation was associ-
ated with BH4 responsiveness in the START study [35],
but non-responder patients carrying the p.Y414C muta-
tion in heterozygosity were also described [36]. In our
study, the same genotype (p.R158Q/p.Y414C) was found
both in a responder and in a non-responder patient (#16,
34). In this case the possible action of modifier genes can-
not be excluded.
Rate of response
The use of a loading test extended to 48 h was import-
ant to detect responsiveness in both the patients with
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Indeed, 4 mPKU and 1 mHPA patients would have been
missed if a 24 h test had been performed. Only one
pseudo-responder patient (#11) was identified (2%). Pa-
tients who cannot increase their tolerance despite a sig-
nificant decrease of plasma Phe during the BH4 loading
test are emerging in the clinical landscape. So far, 3 out
of 14 patients (21%), responders to a 24 h loading test
[37], 2 out of 16 (12.5%) patients, responders to an 8-day
BH4 load [14], and 9 out of 58 patients (15.5%), re-
sponders to a 1 month BH4 load [17] were unable to in-
crease their tolerance on long-term therapy. The low
incidence of pseudo-responders found in the present
study suggests that a 48 h-long loading test performed in
a hospital setting may minimize the risk of false positive
responses.
Predictors of responsiveness
The ability to predict BH4 response in PKU patients
could reduce costs and help guide management of PKU
patients. Besides the impact of the genotype, our results
show that the biochemical phenotype and lower Phe/Tyr
ratio at T0 of the test were significantly different in BH4
responders compared to non-responders.
Long-term therapy with BH4
So far, published papers showed a positive effect of
sapropterin in reducing Phe levels in BH4-responders.
Poor data are available on long-term clinical outcomes
[1]. Few studies described the long-term effect of
sapropterin therapy on tolerance [14,15,38].
The present study showed increased natural protein
intake over the long-term period. Phe tolerance in-
creased also in patients with severe forms of HPA. Des-
pite the dramatic increase of dietary Phe, in 11 patients
(59%) plasma Phe values decreased or remained stable
(Table 5). In the remaining patients (#2, 6, 7, 10, 11, 12),
plasma Phe increased but remained below the Phe target
for age considered in this study. In patient #7, results of
the BH4 withdrawal test demonstrated the efficacy of
BH4 therapy; patient #11 was later shown to be a
pseudo-responder. However, in patients #2, 6, 10 and 12,
we failed to prove definitively the beneficial effect of
BH4 therapy although, under BH4, a good metabolic
control was generally maintained. Adolescence and
adulthood are critical periods for PKU management due
to poor compliance to diet and inadequate metabolic
control. Diet relaxation and optimal metabolic control
under sapropterin therapy is particularly beneficial in
these groups of patients and may improve quality of life
and neuropsychological performances [39].
Eighty-eight percent of patients had a better metabolic
control if the daily BH4 dosage was divided in three
doses. It was suggested that the curve of Phe reductionduring the BH4 loading test could predict if 1, 2 or 3
doses/day of BH4 had to be prescribed [28]. However, in
our study, all BH4-responder patients showed a gradual
and progressive reduction of Phe values during the test
with no evidence of peaks that could let us discriminate
a priori the need of a single vs triple BH4 dose per day.
Patients who resulted as BH4 responders and started
the long-term treatment during adolescence maintained
the same metabolic control at the same dietary regimen
during adulthood. This observation suggests that a higher
growth rate does not explain the observed increase of tol-
erance to Phe.
BH4 withdrawal test
The improvement of dietary Phe intake and of metabolic
control was directly dependent on BH4 assumption, as
further demonstrated by the BH4 withdrawal test. Under
a constant dietary regimen, the BH4 withdrawal test,
performed for the first time in the present study, clearly
showed an increase of plasma Phe ranging from 31 to
87%. At the resumption of therapy, Phe values readily
returned to the previous plasma levels.
Safety and tolerability
The Kuvan® safety sheet reports headache, rhinorrhea,
pharyngolaryngeal pain, gastrointestinal symptoms, cough
and nasal congestion as the most common adverse reac-
tions to sapropterin. In this study, gastrointestinal symp-
toms (epigastric pain and appendicitis-like symptoms)
were reported in three patients (17.6%). In the study by
Burton et al. [9], appendicitis was first described in one
patient 1 month after the discontinuation of the drug.
However, appendicitis is a common disease in the general
population and additional follow-up of large cohorts of
patients is required to ascertain whether the symptoms
are sapropterin-related or not. Headache was found in
nearly 12% of patients. Other adverse events were transi-
ent anorexia and psychotic symptoms. Psychiatric symp-
toms have been reported across the lifespan of individuals
with PKU, especially during adulthood, even among the
early treated ones [40] and probably the observed adverse
effects are not linked to sapropterin. In one patient,
symptoms (epigastralgia and nausea) regressed after
drug discontinuation and did not re-occurred after the
resumption of the treatment showing that, in case of
discontinuation of the treatment due to a drug- related
side effect, the attempt to reintroduce sapropterin may
be done.
Maternal PKU syndrome is still an issue in PKU man-
agement, since a strict metabolic control should be
maintained throughout pregnancy. Sapropterin has been
proposed as an adjuvant to diet for those women who
are unable to achieve low Phe levels, but safety data for
the foetus are scarce. A recent study reported 8 cases of
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nancy who gave birth to normal children in 7 cases and
to a child affected with Potter syndrome in one case
[41]. Here we describe a case of a women treated with
Kuvan® until the 7th week of gestational age, a critical
time window for embryonic development, who gave
birth to a healthy child.
Conclusions
In conclusion, results from this clinical trial of long-term
treatment with BH4 confirmed that BH4 is safe and effect-
ive in increasing tolerance to Phe while keeping a good
metabolic control. The improvement of Phe tolerance is
due to BH4 assumption, as shown by the BH4 withdrawal
test.
As an incidental observation, we reassessed Phe toler-
ance in a subset of PKU patients. Accurate phenotyping of
PKU patients is difficult and insidious and no consensus
exists among different Metabolic Centers. However, there
is increasing need to assess the real tolerance to Phe in
PKU patients to ameliorate quality of life, improve nutri-
tional status, avoid unnecessarily restricted diets, and
interpret the effect of new therapies for PKU.
Additional files
Additional file 1: Phenotypic and genotypic characterization of
HPA subjects.
Additional file 2: Study diagram.
Additional file 3: Body mass index (BMI) of patients on long-term
treatment with BH4.
Additional file 4: Tolerance and plasma Phe values before and after
re-evaluation of Phe tolerance in five patients non-responders to
BH4: a five years follow-up. Columns represent dietary Phe intake
expressed in mg/day. Lines represent median Phe values (micromol/L)
and 10th-90th centile; medians were calculated from plasma Phe values
collected during the 5 years prior to the progressive increase of dietary
Phe and during the 5 years follow-up after the achievement of the new
dietary intake, respectively. All median values under the new dietary
regimen fell into the reference range of plasma Phe for age group.
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